VERSANT VENTURE MANAGEMENT LLC
Q3 2023 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001560009
· CRD 161130
· Exempt reporting adviser
$188.1M Reported Value Total
VERSANT VENTURE MANAGEMENT, LLC reports under management (AUM).
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Exempt Reporting Adviser
WWW.VERSANTVENTURES.COM
Source: Form ADV filed 2026-03-30
Reported value
$188.1M
Quarter over quarter
-6.0%
Holdings
8
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Max Eisenberg
Chief Operating Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2023 13F record
Q3 2023 13F filing summary
| Period of report | September 30, 2023 |
|---|---|
| Filed | November 03, 2023 |
| Form | 13F-HR |
| Reported value | $188.1M |
| Positions | 8 |
| Change in reported value | +123.2% |
| New positions | 1 |
| Exited positions | 1 |
| Position turnover | 22.2% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 13, 2026
|
8 | $109.1M |
|
Q2 2026 13F
Filed Aug 12, 2026
|
8 | $162.6M |
|
Q1 2026 13F
Filed May 5, 2026
|
8 | $141.4M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
7 | $151.1M |
|
Q3 2025 13F
Filed Nov 10, 2025
|
9 | $212.5M |
|
Q2 2025 13F
Filed Aug 11, 2025
|
8 | $82.1M |
|
Q1 2025 13F
Filed May 7, 2025
|
7 | $60.2M |
|
Q4 2024 13F
Filed Feb 12, 2025
|
7 | $86.7M |
|
Q3 2024 13F
Filed Nov 8, 2024
|
6 | $63.6M |
|
Q2 2024 13F
Filed Aug 7, 2024
|
8 | $77.3M |
|
Q1 2024 13F
Filed May 3, 2024
|
7 | $103.1M |
|
Q4 2023 13F
Filed Feb 8, 2024
|
7 | $388.8M |
|
Q3 2023 13F
Filed Nov 3, 2023
|
8 | $188.1M |
|
Q2 2023 13F
Filed Aug 9, 2023
|
8 | $84.3M |
|
Q1 2023 13F
Filed May 11, 2023
|
7 | $48.0M |
|
Q4 2022 13F
Filed Feb 9, 2023
|
7 | $48.3M |
|
Q3 2022 13F
Filed Nov 10, 2022
|
8 | $58.7M |
|
Q2 2022 13F
Filed Aug 11, 2022
|
8 | $65.2M |
|
Q1 2022 13F
Filed May 10, 2022
|
10 | $100.2M |
|
Q4 2021 13F
Filed Feb 11, 2022
|
10 | $187.0M |
28 earlier quarters on file — choose one from the quarter menu above.
Top 8 holdings · Q3 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RYZB RayzeBio, Inc. | $114.5M | 60.87% |
| 2 | RPTX Repare Therapeutics, Inc. | $32.0M | 17.0% |
| 3 | CRSP CRISPR Therapeutics AG | $22.6M | 12.03% |
| 4 | ADVM Adverum Biotechnologies, Inc. | $7.6M | 4.04% |
| 5 | GRTS Gritstone Oncology, Inc. | $6.1M | 3.26% |
| 6 | PASG Passage Bio, Inc. | $3.3M | 1.73% |
| 7 | ALGS Aligos Therapeutics, Inc. | $1.7M | 0.92% |
| 8 | UTRS Minerva Surgical Inc. | $275.3K | 0.15% |
Values as reported on the Q3 2023 Form 13F. Every position is in the holdings table below.